In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Forte Biosciences (FBRX), with a price target of $60.00. The company’s shares closed last Tuesday at $20.61.
According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -7.1% and a 28.9% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.
Currently, the analyst consensus on Forte Biosciences is a Moderate Buy with an average price target of $60.00.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient’s immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.
